Date post: | 13-Feb-2017 |
Category: |
Education |
Upload: | mohit-aggarwal |
View: | 38 times |
Download: | 2 times |
ANTIBIOTIC CHOICE IN ICUANTIBIOTIC CHOICE IN ICU
Ram ChitlangiaPreceptors-
Dr. Rajiva GuptaDr. Sanjeev Sinha
Introduction Epidemiological dataDifferent ICU profilesMicrobiological dataPrinciples of antibiotic useChoice of antibioticsAntimicrobial resistance & its preventionConclusions
Introduction Introduction
Infections are important cause of morbidity & mortality in critically ill patients
Type of infection varies according to type of ICU
Different organisms in different ICU’sGeographical variationIncreasing resistance to antimicrobials
Infections in Critically Ill PatientsInfections in Critically Ill Patients
Bloodstream infectionsPneumoniasGastrointestinal infectionsCNS infectionsUrinary Tract infectionsSkin & Soft Tissue infection
[Crit Care Med, 2004,32, 1510-1526]
Introduction Epidemiological dataDifferent ICU profilesMicrobiological dataPrinciples of antibiotic useChoice of antibioticsAntimicrobial resistance & its preventionConclusions
The European Prevalence of The European Prevalence of Infection in Intensive Care (EPIC) Infection in Intensive Care (EPIC) StudyStudy1- day point prevalence studyICU’s in 17 countries in western Europe,
excluding CCU, PICU & special care infant units
All patients occupying (>10 yrs age) an ICU bed over 24 h period
Total 1417 ICU’s10038 patient case reports [JAMA 1995,274(8),639-44]
Results of EPIC StudyResults of EPIC Study
Total infected = 4501 pts.(44.8 %)
ICU acquired infection = 2064 pts.(20.6 %)
Results of EPIC StudyResults of EPIC Study
46.9
17.8 17.612
05
101520253035404550
Perc
enta
ge
Pneumonia LRTI UTI BSI
Results of EPIC StudyResults of EPIC Study34.4
30.1 28.7
19.1 17.1
0
5
10
15
20
25
30
35Pe
rcen
tage
Ent
erob
acte
riac
eae
S.au
reus
P.ae
rugi
nosa
CoN
S
Fung
i
Results of EPIC StudyResults of EPIC StudyRisk factors for ICU acquired infections-
– Increasing length of ICU stay (>48 hrs)– Mechanical ventilation– Diagnosis of trauma– Central venous catheterization– Pulmonary artery catheterization– Urinary tract catheterization– Stress ulcer prophylaxis
[JAMA 1995,274(8),639-44]
Results of EPIC StudyResults of EPIC Study
Risk of ICU deaths-– ICU acquired pneumonia (OR = 1.91)– Clinical sepsis (OR = 3.50)– Bloodstream infection (OR = 1.73)
[JAMA 1995,274(8),639-44]
National Nosocomial Infection National Nosocomial Infection Surveillance System (NNIS) Study Surveillance System (NNIS) Study 19991999
1992-1997
181,993 patients in medical ICU in the US
Most frequent nosocomial infection- UTI (31 %)
[Crit Care Med 1999, 27(5), 853-54]
3127
19
0
5
10
15
20
25
30
35
Perc
enta
ge
UTI Pneumonia BSI
Results of NNIS StudyResults of NNIS Study
Introduction Epidemiological dataDifferent ICU profilesMicrobiological dataPrinciples of antibiotic useChoice of antibioticsAntimicrobial resistance & its preventionConclusions
Medical ICUMedical ICU
Pneumonia
Septicemia
COAD with Ac. exacerbation
CNS Infections
Surgical ICUSurgical ICU
Post operative patients
Septicemia
Intraabdominal infections
Trauma
Pediatric ICUPediatric ICU
Post operative patients Septicemia Respiratory tract
infections Neurological illnesses Others e.g.renal,
gastrointestinal etc
Introduction Epidemiological dataDifferent ICU profilesMicrobiological dataPrinciples of antibiotic useChoice of antibioticsAntimicrobial resistance & its preventionConclusions
Ventilator Associated Pneumonia Ventilator Associated Pneumonia (VAP) Pathogens(VAP) Pathogens
1. Staph. aureus
2. Pseudomonas aeruginosa
3. Enterobacter spp.
Am J Infect Control 1999, 27, 520-32
MICU % SICU % PICU % CCU % CTVS % NSICU %
TOTAL %
Enterobacter 8.6 12.8 9.8 9.8 13.1 10.5 11.2E.Coli 3.5 4.9 3.6 4.2 4.8 4.6 4.3K.Pneumoniae 7.7 7.2 5.4 8.4 5.9 7.5 7.2H influenzae 1.5 4.4 9.3 3.1 5.8 7.4 4.3P aeruginosa 21.2 17.2 22.4 14.9 13.1 12.1 17.0S aureus 21.4 17.0 16.4 20.2 11.3 21.6 18.1Enterococcus 1.7 1.8 0.9 1.8 2.3 1.3 1.7C albicans 5.0 3.9 2.0 6.3 6.3 4.3 4.7Others 29.4 30.9 30.2 31.3 37.4 30.7 31.5Total 100 100 100 100 100 100 100
CDC NNIS Report , Am J Infect Control
Ventilator Associated Pneumonia Ventilator Associated Pneumonia (VAP) Pathogens(VAP) Pathogens
VAP Rates in ICU , NNIS ReportVAP Rates in ICU , NNIS Report
Type of ICU No. of units Ventilator days
Pooled mean* median
MICU 82 111,764 5.0 3.6
SICU 86 107,162 9.9 8.3
PICU 45 49,239 2.9 2.2
CCU 49 30,586 4.2 3.1
CTVS ICU 43 36,871 7.9 5.1
NSICU 25 19,149 12.9 9.6
[Am J Infect Control 2003, 31, 481-98]*Per thousand ventilator days
Urinary Tract Infection (UTI) PathogensUrinary Tract Infection (UTI) Pathogens
1. E. coli
2. Candida albicans
3. Enterococcus
[Am J Infect Control 1999, 27, 520-32]
NNIS Report 1992-99, UTI PathogensNNIS Report 1992-99, UTI Pathogens
MICU %
SICU % PICU % CCU % CTVS %
NSICU %
TOTAL %
Enterobacter 4.1 6.2 9.5 3.9 5.9 5.1 5.1E.Coli 13.7 14.6 19.2 26.0 12.5 28.3 17.5K.Pneumoniae 6.3 6.1 6.8 7.8 6.1 7.9 6.2P.Aeruginosa 9.7 13.1 14.3 6.5 12.6 10.9 11.0S aureus 1.8 1.3 1.3 2.3 0.6 1.9 1.6Staph.coagulase -ve 2.3 1.9 4.3 3.2 1.6 3.8 2.7Enterococcus 14.2 14.5 9.6 14.3 8.5 11.9 13.8C albicans 20.8 16.3 14.0 10.2 21.0 8.1 15.8Others 27.1 26.0 21.0 25.8 31.2 22.1 26.3Total 100 100 100 100 100 100 100
UTI Rates in ICU, NNIS Report UTI Rates in ICU, NNIS Report
Type of ICU No. of units Urinary catheter days
Pooled mean* Median
MICU 142 1,399,462 6.2 5.5
SICU 161 1,640,514 5.1 4.4
PICU 75 301,096 4.7 4.3
CCU 114 567,232 5.4 7.3
CTVS ICU 71 655,566 3.1 2.5
NSICU 52 329,201 7.7 6.7
[Am J Infect Control 2003, 31, 481-98]*Per thousand urinary catheter days
Blood Stream Infection (BSI)- Blood Stream Infection (BSI)- PathogensPathogens
1. Coagulase negative staphylococci
2. Enterococcus
3. Staphylococcus aureus
[Am J Infect Control 1999, 27, 520-32]
NNIS Report 1992-99, BSI pathogensNNIS Report 1992-99, BSI pathogens
MICU %
SICU % PICU % CCU % CTVS %
NSICU %
TOTAL %
Enterobacter 3.1 5.8 6.8 2.9 6.2 4.1 4.9E.Coli 2.1 2.2 3.0 2.8 2.0 2.6 2.3K.Pneumoniae 3.9 4.0 4.3 2.2 2.2 3.1 3.4P.Aeruginosa 3.6 4.1 4.9 2.1 2.6 3.7 3.8S aureus 14.0 10.4 9.7 23.2 9.0 13.1 12.6Staph.coagulase -ve 35.7 36.1 37.7 37.0 42.7 44.6 37.3Enterococcus 16.5 15.3 10.7 10.2 14.3 11.3 13.5C albicans 6.3 4.5 5.1 2.6 4.4 3.0 5.0Others 14.8 17.6 17.8 17 16.6 14.5 17.2Total 100 100 100 100 100 100 100
BSI Rates in ICU, NNIS ReportBSI Rates in ICU, NNIS Report
Type of ICU No. of units Central line days
Pooled mean* Median
MICU 143 975,318 5.7 5.0
SICU 160 1,267,959 5.2 4.7
PICU 79 428,104 7.3 5.9
CCU 114 363,976 4.2 4.2
CTVS ICU 71 598,118 2.9 2.2
NSICU 52 180,581 4.8 4.1
[Am J Infect Control 2003, 31, 481-98]*Per thousand central line days
AIIMS Data – ICU Infection 2003-04AIIMS Data – ICU Infection 2003-04
ICU Bacteremia (%)
RTI (%) UTI (%) SSI (%)
MICU 2 18 0 0.6
SICU 9 5 0.8 23
Special(AB8) 24 23 3 4
Gastro 8 5 0.4 1
Paed.med 13 14 0.4 4
Paed.surg 11 19 6 34
Neonatal 4 1 0 4
(Source: Deptt. of Microbiology,AIIMS)
AIIMS Data – Common PathogensAIIMS Data – Common Pathogens
Gram negative-– Acinetobacter spp.– Pseudomonas spp.– Klebsiella pneumoniae– E.coli– Enterobacter spp.
Gram positive –– Staphylococcus aureus – Coagulase negative
staphylococci (CoNS)– Enterococcus spp.– Streptococcus
(Source: Deptt. of Microbiology,AIIMS)
AIIMS Data - PrevalenceAIIMS Data - Prevalence
Gram negative bacteria (GNB) contribute about 60 % of total bacteriologically proven infection
Gram positive bacteria (GPC) constitute the rest of 40 %
Recent trend is increase in GPC infection especially in ICU’s & patients on intravascular devices
(Source: Deptt. of Microbiology,AIIMS)
AIIMS Data – C 2 ICU AIIMS Data – C 2 ICU Total no. of patients = 80Nosocomial infections = 25 episodes
– VAP = 23 episodes– BSI = 1 episode– UTI = 1 episode
Organisms (VAP)–– Acinetobacter spp. = 60.8 %– Pseudomonas aeruginosa = 17.3 %– Klebsiella = 13.04 %
Introduction Epidemiological dataDifferent ICU profilesMicrobiological dataPrinciples of antibiotic useChoice of antibioticsAntimicrobial resistance & its preventionConclusions
Principles of Antibiotic UsePrinciples of Antibiotic Use
Goal – To choose a drug selectively active against the most likely infecting organism & least potential to cause toxicity
Empirical / Definitive / Prophylactic
Principles of Antibiotic UsePrinciples of Antibiotic Use
Whether or not antibiotic indicated ?
Microbial sensitivity to agent
Pharmacokinetic factors
Host factors
Introduction Epidemiological dataDifferent ICU profilesMicrobiological dataPrinciples of antibiotic useChoice of antibiotics in ICUAntimicrobial resistance & its preventionConclusions
Choice of Antibiotic in ICUChoice of Antibiotic in ICU
Community acquired pneumoniaVentilator associated pneumoniaIntravascular catheter related infectionUrinary tract infectionIntra abdominal infectionCentral nervous system infection
Community Acquired Pneumonia (CAP) Community Acquired Pneumonia (CAP) in ICUin ICU
A common and serious illnessSixth leading cause of death in USThe number one cause of death from
infectious diseasesSevere community acquired pneumonia
requires ICU admission
[Am J Respir Crit Care Med 2001, 163,1730-54]
Severe CAP - EtiologySevere CAP - EtiologyOrganisms-
– S.pneumoniae– Atypical pathogens (Chlamydia pneumoniae,
M.pneumoniae, Legionella)– Enteric gram negatives– H.influenzae– Staph.aureus } specific risk– Pseudomonas aeruginosa } factors– Respiratory tract viruses
Severe CAP - EtiologySevere CAP - Etiology50-60 % of patients with severe CAP have
unknowm etiologyDrug resistant S. pneumoniae (DRSP)-
– Intermediate = penicillin MIC 0.12-0.20 μg/mL – High = penicillin MIC ≥ 2 μg/ mL– Clinical relevance – controversial
CDC study- Breakpoint for clinically relevant resistance to penicillin is MIC ≥ 4 μg/mL
[Am J Public Health 2000; 90,223-29]
Treatment Treatment Organism specific therapy is ideal Limited diagnostic methods Patients with severe CAP-
– With no risk factors for pseudomonas– With risk factors for pseudomonas
Risk factors- – Structural lung disease (Bronchiectasis)– Corticosteroid therapy (>10 mg prednisolone per day)– Broad spectrum antibiotic therapy for > 7 days in the past
month– Malnutrition
TreatmentTreatmentPatients with no risk factors for pseudomonas-
– Intravenous β- lactam (cefotaxime, ceftriaxone) plus either– Intravenous macrolide (azithromycin) or
Intravenous fluoroquinolone
[Am J Respir Crit Care Med 2001, 163,1730-54]
TreatmentTreatmentPatients with risk factors for pseudomonas-
– Selected I.V. antipseudomonal β- lactam (cefepime, imipenem, meropenem, piperacillin/tazobactam)
plus I.V.antipseudomonal quinolone (ciprofloxacin)
OR– Selected I.V. antipseudomonal β- lactam plus I.V. Aminoglycoside Plus either I.V. macrolide (Azithromycin)
or I.V. nonpseudomonal fluoroquinolone [Am J Respir Crit Care Med 2001, 163,1730-54]
TreatmentTreatmentIf patient is allergic to β- lactam, it should be
replaced with Aztreonam and combined with aminoglycoside & antipseudomonal FQ
The β- lactam used should be active against DRSP
Agents active against pseudomonas are not recommended as primary therapy when this organism is not suspected
Duration Of TreatmentDuration Of TreatmentFactors-
– Coexisting illness and/or bacteremia– Severity of illness at onset of antibiotic therapy– Subsequent hospital course
In general-– S.pneumoniae – 7-10 d– Myco.pneumoniae – 10-14 d– Chlamydia pneumoniae – 10-14 d– Legionella – 10-14 d
[Am J Respir Crit Care Med 2001, 163,1730-54]
Switch to Oral TherapySwitch to Oral TherapyCriteria –
– Improvement in cough & dyspnea– Afebrile (<100 °F ) on two occasions 8 h apart– White cell count decreasing– Functioning G.I. tract with adequate oral intake
Narrowest spectrum agent according to etiologic organism with an appropriate pharmacokinetic profile should be chosen
Compliance is very important
Ventilator Associated Pneumonia In ICUVentilator Associated Pneumonia In ICU
VAP in ICUVAP in ICU
A pneumonia is considered to be ventilator associated when it occurs after intubation & is judged not to have incubated before an artificial airway is put in place
Incidence = 9-68 %Mortality = 33-71 % (Am Rev Respir Dis 1990,142,523-528)
VAP in ICUVAP in ICU
Mechanical ventilation (MV) was associated with 86 % of episodes of hospital acquired pneumonia in the NNIS study
(Crit Care Med 1999,27(5) 887-92)
The risk of VAP increases linearly by approximately 1 % per day in the intubated patient for the first 30 days
(Am Rev Respir Dis.1989, 139(4) 877-884)
VAP in ICUVAP in ICU
VAP is associated with significant increase in morbidity, mortality, length of ICU stay and costs.
Jiminez et.al- – The mean duration of MV increased from 10 to
32 days when VAP developed in intubated patient.
[Crit Care Med 1989,17(9) 882-885]
VAP in ICUVAP in ICU
Rello et.al- retrospective study Patients with VAP had-
- Longer duration of MV (14.3±15.5 d versus 4.7±7 d)- ICU stay (11.7±7 d versus 5.6±6.1 d)- Hospital stay (25.5±22.8 d versus 14±14.6 d) [Chest 2002 122(6)2115-2121]
Risk factors for development of VAPRisk factors for development of VAP
Shock Multiorgan failure Worsening respiratory failure Ultimately or rapidly fatal underlying illness Age > 60 years Supine position Inappropriate or prior antibiotic treatment [Chest Surg Clin N Am 2002, 379-395]
Microbiology of VAPMicrobiology of VAP
Gram negative bacilli (GNB) and staphylococcus aureus are the most common causes of VAP
Among GNB, Pseudomonas aeruginosa and Acinetobacter baumani are most frequent isolates.
The role of anaerobes has not been thoroughly investigated
[CDC NNIS System; Am J Infect Control 1999,27, 520-532]
Treatment of VAPTreatment of VAP
Empiric or Directed TreatmentMonotherapy or Combination therapyAntibiotic RegimenModification of Initial Empiric TreatmentDuration of Treatment [Drugs & Aging 2001,18(3),189-200]
VAP-Empiric or Directed TreatmentVAP-Empiric or Directed TreatmentEmpiric treatment is reasonableNo role of prophylactic antibioticsNon availability of accurate, cost effective and
rapid diagnostic proceduresChoice of therapy should be based on
– Knowledge of most frequent pathogen and their pattern of susceptibility
– Specific risk factors esp. prior antibiotic use– Time since admission to hospital– Duration of MV before development of VAP
VAP-Monotherapy or Combination VAP-Monotherapy or Combination TherapyTherapy
55 % of VAP are polymicrobial in natureCombination therapy is preferableReduces appearance of resistanceSynergistic effects of antibioticsDecreases risk of inadequate treatment before
microbiological data are available
(AJRCCM 1998,157,531-9)
VAP-Monotherapy or Combination VAP-Monotherapy or Combination TherapyTherapy
Disadvantages – higher risk of toxicity esp. in regimens with aminoglycosides, higher costs
Knowledge of prior antibiotic treatment is very important as the organism may be resistant to those drugs
VAP-Antibiotic RegimenVAP-Antibiotic Regimen
Patients with VAP can be divided into two groups-– Early onset & without risk factors– Any onset & with risk factors
The definition of early onset varies from 4 to 7 days according to various guidelines.
VAP-Antibiotic RegimenVAP-Antibiotic RegimenEarly onset VAP & without risk factors-
First choice- Second or third generation nonpseudomonal
cephalosporins or combined β -lactam/ β -lactamase inhibitor
If patient is allergic to these- Fluoroquinolones or clindamycin + aztreonam
VAP-Antibiotic RegimenVAP-Antibiotic Regimen Any onset VAP & with risk factors-
First choice- – Aminoglycosides or ciprofloxacin plus one of the following:– Antipseudomonal penicillin– β-lactam/β-lactamase inhibitor– Ceftazidime or Cefoperazone– Imipenem– Azteonam ± Vancomycin (AJRCCM 153,1995,1711-25)
VAP-Antibiotic RegimenVAP-Antibiotic Regimen
Patients at risk of aspiration pneumonia should receive antibiotics with anaerobic activity
A glycopeptide may be added if the prevalence of MRSA is high & especially if β-lactams have been given previously
VAP-Modification of Initial VAP-Modification of Initial RegimenRegimen
Adjust therapy after availability of microbiological data.
Aim – narrower spectrum antibioticsTherapeutic de-escalation advisableModify if appearance of resistant organismsPoor clinical response
VAP-Modification of Initial VAP-Modification of Initial RegimenRegimen
New antibiotic must be from different class of drugs
New respiratory samples should be sent before any change in antibiotic therapy
VAP-Duration of TreatmentVAP-Duration of Treatment There must be clinical improvement & afebrile period of at
least 48 hrs. before stopping antibiotics
P.aeruginosa or A.baumani infections should be treated for minimum of 14-21 days
Patients with multilobar involvement, malnutrition, severe debilitation, cavitation, or a necrotizing GNB pneumonia also require 14-21 days treatment
(AJRCCM 1995,153,1711-25)
Prevention of VAP – Physical StrategiesPrevention of VAP – Physical Strategies Oral endotracheal tube Recommended Ventilator circuit change Recommended Heat & moisture exchanger Recommended Weekly change of humidifier Recommended Closed suction system Recommended Change in suction system Recommended Drainage of subglottic secretions Consider Systematic search for sinusitis No recommendation Chest physiotherapy No recommendation Early tracheostomy No recommendation
(Ann Intern Med 2004;141:305-313)
Prevention of VAP – Positional StrategiesPrevention of VAP – Positional Strategies
Semi-recumbent positioning Recommended
Kinetic beds Consider
Prone positioning No recommendation
(Ann Intern Med 2004;141:305-313)
Prevention of VAP – Pharmacologic Prevention of VAP – Pharmacologic StrategiesStrategies
Sucralfate Not recommended Intratracheal antibiotics Not recommended Topical antibiotics Not
recommended Intravenous(I.V.) antibiotics No
recommendation I.V. and topical antibiotics No
recommendation(Ann Intern Med 2004;141:305-313)
Intravascular Catheter Related Intravascular Catheter Related Infections In ICUInfections In ICU
IVC Related Infections in ICUIVC Related Infections in ICU
Major cause of morbidity & mortality in critically ill patients
Organisms- – Coagulase negative staphylococci– Staph. Aureus– Aerobic gram negative bacilli– Candida albicans
(IDSA Guidelines; Clin Infect Dis 2001;32,1249-72)
Source of IVC Related InfectionsSource of IVC Related Infections
IVC Related Infections in ICUIVC Related Infections in ICU
Byers et al – Meta analysis– 2573 catheter related infections– Case fatality rate was 14 %– 19 % of these deaths were attributed to catheter
related infectionMortality rate attributed to S. aureus was
significantly higher than others
Diagnosis Diagnosis
Clinical diagnosis – unreliable Semiquantitative (roll plate) or Quantitative (vortex or
sonication methods) catheter culture techniques are most reliable diagnostic methods
A yield of ≥ 15 cfu by semiquantitative or ≥ 100 cfu by quantitative culture from a catheter , with accompanying signs of local or systemic infection is indicative of catheter related infection
(IDSA Guidelines; Clin Infect Dis 2001;32,1249-72)
Treatment Treatment
Vancomycin – where methicillin resistant staphylococci (MRSA) is common
Nafcillin or Oxacillin – where MRSA or MRSE are rare
Linezolid – if pt. is allergic to vancomycin3rd or 4th Gen. cephalosporin added – in
immunocompromised or severely ill pts.Amphotericin – if possibility of fungemia
[Clin Chest Med 24(2003) 645-669]
When to Remove IVC ?When to Remove IVC ?
If pt. have signs of infection or inflammation overlying the catheter exit site
Clinical evidence of sepsisBlood culture results are positiveInfection due to staph. aureusPatients with fungemia
[Clin Chest Med 24(2003) 645-669]
Duration of TreatmentDuration of Treatment
Uncomplicated infections – 10-14 d
BSI due to CoNS – 5-7 d (if IVC removed) 10-14 d (if IVC not removed)
BSI due to Candida – 14 d after last positive culture
[Clin Chest Med 24(2003) 645-669]
Antibiotic Lock TherapyAntibiotic Lock TherapyInability of antibiotics to kill microorganism
growing in biofilmAntibiotic concentrations must be 10-100 times
greater to kill sessile (biofilm) than to kill planktonic (in solution) bacteria
Filling the catheter lumen with pharmacologic concentrations of antibiotics & leaving them there for hours or days.
(IDSA Guidelines; Clin Infect Dis 2001;32,1249-72)
Prevention of IVC Related InfectionPrevention of IVC Related Infection
Sterile barrier precautions e.g. gloves, gowns,masks, large drapes
Chlorhexidine for skin antisepsis prior to catheter placement
Removal of “idle” catheters Antimicrobial or Antiseptics impregnated
catheters
Prevention of IVC Related InfectionPrevention of IVC Related Infection
Avoidance of femoral site for catheter insertion
Rotation of peripheral catheters to a new site at specified intervals
Applying disposable transducers for pressure monitoring
Complicated Intra-abdominal infectionsComplicated Intra-abdominal infections
Infections that extend beyond the hollow viscus of origin into the peritoneal space & associated either with abscess formation or peritonitis
Can be –– Community acquired– Hospital acquired
(Clin Infect Dis 2003;37, 997-1005)
Pathogens Pathogens
Hospital acquired:– P.aeruginosa– Enterobacter spp.– Proteus spp.– MRSA– Enterococci– Candida spp.
Community acquired:– Gram neagtive aerobes &
facultative organisms e.g. E.coli
– Anaerobes e.g. B.fragilis– Streptococci– Enterococci
Antimicrobial therapyAntimicrobial therapy
Antibiotics should be started once intra abdominal infection is suspected
Goals – – Elimination of infecting microorganism– To decrease the likelihood of recurrence– To shorten the time to resolution of signs
&symptoms of infection
Treatment-Community Acquired InfectionTreatment-Community Acquired Infection
MILD-MODERATE– Single agent –
• Ampicillin/sulbactam• Ticarcillin/clavulanic acid• Ertapenem
– Combination –• Cefazolin/ cefuroxime plus
Metronidazole• Cipro /levo/ gati/
moxifloxacin with Metronidazole
SEVERE INFECTIONS-– Single agent-
• Piperacillin/tazobactam• Imipenem/ cilastatin• Meropenem
– Combination –• 3rd / 4th gen. cephalosporin
plus Metronidazole• Ciprofloxacin plus
Metronidazole• Aztreonam plus
Metronidazole (Clin Infect Dis 2003;37, 997-1005)
Treatment- Hospital Acquired InfectionTreatment- Hospital Acquired Infection
Complex multidrug regimens (e.g. an aminoglycoside/ quinolone/ carbapenem & vancomycin) is recommended
Treat according to local nosocomial resistance patterns
Modify treatment according to results of microbiological data
Urinary Tract Infection (UTI) in ICUUrinary Tract Infection (UTI) in ICU
Urinary Tract Infection (UTI) in ICUUrinary Tract Infection (UTI) in ICUMost common nosocomial infection
Significant morbidity & mortality if complicated by bacteremia or urosepsis
Increased length of hospital stay
Increased cost[NNIS Study, Crit Care Med 1999,27(3),853-54]
Nosocomial UTINosocomial UTI Risk Factors-
– Presence of indwelling urinary catheter- M. Imp.– Female gender– Extended ICU stay
Complications – Urosepsis– Age >60 years– Extended hospital stay– Extended duration of urinary catheterization
(Infection 1999; 27(1); 16-22)
Nosocomial UTI -EtiologyNosocomial UTI -Etiology
E.coliCandida albicansP aeruginosaEnterococcus spp.Klebsiella pneumoniae
(Clin Chest Med 2003; 24,645-69)
Nosocomial UTI- TreatmentNosocomial UTI- Treatment
Piperacillin/tazobactam or ticarcillin/clavulanateImipenem / MeropenemCiprofloxacin / Levofloxacin / GatifloxacinAmpicillin with GentamicinCeftazidime with VancomycinAntifungal therapy if strong clinical suspicion of
disseminated candidiasis & pt. is unstable
(Clin Chest Med 2003; 24,645-69)
CNS Infections in ICU CNS Infections in ICU Pyogenic Meningitis Pyogenic Meningitis
Organisms
Hospital acquired:– Staphylococci– Gram negatives
including P.aeruginosa
Community acquired:– S. pneumoniae– N. meningitidis– Gr. B streptococci– L. monocytogenes
HPIM 16th Ed.
Treatment of Pyogenic Meningitis Treatment of Pyogenic Meningitis
Community acquired –– Cefotaxime / Ceftriaxone + Vancomycin
Hospital acquired –– Ampicillin + Ceftazidime + Vancomycin
Introduction Epidemiological dataDifferent ICU profilesMicrobiological dataPrinciples of antibiotic useChoice of antibioticsAntimicrobial resistance & its preventionConclusions
Antimicrobial Resistance & its PreventionAntimicrobial Resistance & its Prevention
Rapid emergence & spread of antibiotic resistant bacteria Important variable related to patient outcomes Risk factors –
– Use of antimicrobial agents– Prolonged hospital stay– Presence of invasive devices
– Inadequate infection control practice
[Ann Intern Med 2001, 134, 298-314]
AIIMS Data – Resistance PatternAIIMS Data – Resistance Pattern
Staph. aureus ─ 40 % MRSA ─ 99 % β- lactamaseCoNS ─ 80 % MRSACiprofloxacin – overall 45 % sensitive but
25 % in MRSAAll are sensitive to vancomycin, teicoplanin
& linezolid
(Source: Deptt. of Microbiology,AIIMS)
AIIMS Data – Resistance PatternAIIMS Data – Resistance Pattern
Enterococcus spp.-– HLAR – 50-55 %– VRE - <1 %
Gram negative bacteria –– Ciprofloxacin – 70-80 %– Amikacin - 40-50 %– Piperacillin - 30-40 %– 3rd & 4th Gen. cephalosporins – 60-70 %
(Source: Deptt. of Microbiology,AIIMS)
AIIMS Data – Resistance PatternAIIMS Data – Resistance Pattern
β – lactamase in GNB –– ESBL - 75-80 %– β-lactam/ β-lactamase inhibitor combination
(pip/tazo, cefotaxime/sulb, ticar/clav) – resistance in 10 % of ESBL
– Carbapenems – resistance in 10 % of ESBL
(Source: Deptt. of Microbiology,AIIMS)
Strategies for PreventionStrategies for Prevention
Antimicrobial strategies
Non antimicrobial strategies
[Ann Intern Med 2001, 134, 298-314]
Antimicrobial strategy for preventionAntimicrobial strategy for prevention
Limit unnecessary antimicrobial administration-– Develop hospital based guidelines for antibiotic use– Hospital formulary restriction– Use of narrow spectrum or older antibiotics– Quantitative cultures & assessment for nosocomial
pneumonia– Education & professional detailing on antibiotic use
for physicians
[Ann Intern Med 2001, 134, 298-314]
Antimicrobial strategy for preventionAntimicrobial strategy for prevention
Optimize antimicrobial effectiveness –– Avoid inadequate treatment– Combination antimicrobial treatment– Antibiotic cycling & scheduled antibiotic changes– Area specific empirical antimicrobial therapy– Limit short course antibiotic prophylaxis to
clinically validated indications– Avoid routine antimicrobial decontamination of
aerodigestive tract in ICU
Nonantimicrobial strategy for preventionNonantimicrobial strategy for prevention
Primary prevention –– Reducing length of hospital stay– Minimization of CVC use– Vaccines
Prevention of horizontal transmission –– Hand washing– Decreasing workload in ICU– Gloves & Gowns [Ann Intern Med 2001, 134, 298-314]
Introduction Epidemiological dataDifferent ICU profilesMicrobiological dataPrinciples of antibiotic useChoice of antibioticsAntimicrobial resistance & its preventionConclusions
Conclusions Conclusions
Antibiotics – Most commonly used as well as misused
Empirical therapy usually necessary in ICU’sChoice should be based on local microbial patternEmerging problem of antimicrobial resistanceAim – Restrict the use of antibioticsProphylactic antibiotics should be avoided